During leukemia research, a group of scientists at Johns Hopkins Kimmel Cancer Center stumbled upon findings that are of particular interest to the multiple sclerosis community. The researchers discovered that by interfering with a blood cell growth gene (called FLT3) they may be able to stop faulty immune responses. This discovery could take MS treatment a step further. Currently, steroids are used to suppress harmful T-cells, but scientists believe they could stop autoimmune attacks altogether. The complete article is published in Proceedings of the National Academy of Sciences (November 15 edition).
Submitted 12/1/2005 1:47:31 PM